Effects of dexmedetomidine analgesia on immune function of patients with abdominal malignant tumor

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-14004896

Enrollment

Unknown

Registered

2014-06-09

Start date

2014-07-21

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Abdominal malignancies

Interventions

1:Fentanyl PCA

2:dexmedetomidine

Eligibility

Age

20 Years to 70 Years

Inclusion criteria

Inclusion criteria: Abdominal malignancies; tumor stage I to II; surgical operation; no allergy to alpha 2 adrenoceptor agonist

Exclusion criteria

Exclusion criteria: Patients who refused to take part in the study were not included.

Design outcomes

Primary

Measure	Time frame
Visual anolog score;FOXP3;CD4+ Treg;CD25+ Treg;TGF-beta;	—

Contacts

Public ContactWang Xiuqin

jasmine75@163.com+86 13665416586

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026